Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 1:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 3,785 matching trials from the live ClinicalTrials.gov search.
Conditions
Myelofibrosis (MF)
Interventions
Ruxolitinib, Navitoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients - Seroprotection

NCT04531657
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions
AU-011, Suprachoroidal Microinjector, PDT Laser
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Glioblastoma Multiforme, Glioblastoma, GBM
Interventions
Nanoliposomal Irinotecan, Temozolomide
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Legg Calve Perthes Disease
Interventions
Osteotomy + Long Term Non-Weight Bearing, Osteotomy + Short Term Non-Weight Bearing, Nonoperative Observation, Multiple Epiphyseal Drilling
Procedure
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
1 Year to 18 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Conditions
Solid Tumors
Interventions
STA-9090
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
25 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Santa Monica, California • Kettering, Ohio
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Simeprevir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more
Conditions
Relapsed and Refractory Multiple Myeloma
Interventions
Ixazomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
Tampa, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more
Conditions
Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Conditions
AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Interventions
Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS
Drug · Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Advanced Solid Tumors, Lymphomas
Interventions
Camptothecin-20-O-Propionate Hydrate (CZ48)
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oxaliplatin, leucovorin calcium, vorinostat, fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Buffalo, New York
Conditions
HIV
Interventions
Tesamorelin for injection
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
31
States / cities
Bakersfield, California • Fountain Valley, California • Los Angeles, California + 22 more
Conditions
Tumors
Interventions
surufatinib
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 5 more
Conditions
Healthy
Interventions
amikacin/fosfomycin
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Healthy Participants
Interventions
PF-06954522, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
Interventions
VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide, Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT), Mycophenolate mofetil (MMF), Tacrolimus
Radiation · Drug · Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Conditions
AL Amyloidosis
Interventions
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Conditions
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Neoplasm, Plasma Cell Dyscrasia, Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Plasma Cell Leukemia
Interventions
Fludarabine, Cyclophosphamide, Total body irradiation, Tacrolimus, Mycophenolate mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
Interventions
Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Conditions
High Risk Meningioma, Recurrent Meningioma
Interventions
⁶⁸Ga-Dotatate PET and MRI Guided Radiation Therapy, Magnetic Resonance Imaging (MRI), 68Ga-Dotatate PET Imaging, MD Anderson Symptom Inventory Bain Tumor form (MDASI-BT), EuroQol-5 Dimension (ED-5D)
Radiation · Diagnostic Test · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Brain Metastases
Interventions
Temozolomide, Valproic Acid, Whole Brain Radiation Therapy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida